SCHEMBL5765900

SCHEMBL5765900

CCn1c(=O)oc2cc(N3C[C@H](C(=O)O)OC3=O)ccc21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
SIGMAR1 Q99720 2/20 0.40
MAPT P10636 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MAOA P21397 3/20 0.37
MIF P14174 1/20 0.36
APEX1 P27695 1/20 0.36
LMNA P02545 2/20 0.36
MAOB P27338 2/20 0.36
PTGS1 P23219 1/20 0.36
CALML3 P27482 1/20 0.36
SDHA P31040 1/20 0.36
RORC P51449 1/20 0.36
SLC6A2 P23975 1/20 0.35
HTR2A P28223 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3035095 0.91 MAOA (0.46) ALDH1A1SMN1; SMN2SIGMAR1MAPTRXFP1
SCHEMBL3035077 0.88 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2SIGMAR1MAOALMNA
SCHEMBL5766092 0.85 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MAPTMAOALMNA
SCHEMBL3045592 0.84 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2MAPTRXFP1LMNA
SCHEMBL5764674 0.82 MAOA (0.37) ALDH1A1MAOALMNAMAOBPTGS1
SCHEMBL3040902 0.81 MAOA (0.42) MAOALMNAMAOBPTGS1CALML3
SCHEMBL5762003 0.79 CNR2 (0.39) SIGMAR1MAPTMAOA
SCHEMBL3039160 0.78 MAOA (0.46) SMN1; SMN2MAOALMNAMAOBPTGS1
SCHEMBL3045912 0.76 MAOA (0.48) ALDH1A1SMN1; SMN2MAOALMNASLC6A2
SCHEMBL3029041 0.74 MAOA (0.47) MAOALMNAMAOBPTGS1CALML3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7141588-B2 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PFIZER, INC. (US) 2006-11-28 US disclosed
EP-1478629-B1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN CO LLC (US) 2006-10-11 EP disclosed
US-6919329-B2 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY (US) 2005-07-19 US disclosed
EP-1478629-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2004-11-24 EP disclosed
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-07-29 US disclosed
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives PHARMACIA & UPJOHN COMPANY 2004-03-04 US disclosed
WO-2003072553-A1 N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS PHARMACIA & UPJOHN COMPANY (US) 2003-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147760-A1 N-aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 ALDH1A1 956/4885SMN1; SMN2 2043/4885SIGMAR1 1597/4885
US-20040044052-A1 N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives OXA1L, AADAC, MT-ND5 ALDH1A1 956/4885SMN1; SMN2 2043/4885SIGMAR1 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.